Korean J Dermatol.  2011 Jan;49(1):50-52.

Leukocytoclastic Vasulitis Induced by Gefitinib

• Hong JW
• Jeon SY
• Lee KY
• Song KH
• Kim KH
• Kim YH

Abstract

Gefitinib (Iressa(R), AstraZeneca) is an oral form of an anticancer drug called epidermal growth factor receptor-tyrosine kinase inhibitor. It is widely used for various solid cancers, including lung cancer. Cutaneous adverse reactions induced by gefitinib have recently been reported with an incidence ranging from 49% to 100%, and they include acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail change and disorders of the mucous membranes, eyes and hair. To the best of our knowledge, no cases of leukocytoclastic vasculitis associated with gefitinib have ever been published in the Korean medical literature, and there have been only four such reported cases in other countries. Herein, we report on a case of leukocytoclastic vasulitis induced by gefitinib in a patient with lung cancer.

Keyword

Gefitinib; Iressa(R); Leukocytoclastic vasculitis

MeSH Terms

Epidermal Growth Factor
Exanthema
Eye
Hair
Humans
Hyperpigmentation
Incidence
Lung Neoplasms
Mucous Membrane
Nails
Phosphotransferases
Pruritus
Quinazolines
Skin
Vasculitis
Vasculitis, Leukocytoclastic, Cutaneous
Epidermal Growth Factor
Phosphotransferases
Quinazolines
Vasculitis, Leukocytoclastic, Cutaneous